Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The study consists of two parts, the first part is a randomized, open-label,
active-controlled study to evaluate the efficacy and safety of Fruquintinib in combination
with Sintilimab versus axitinib or everolimus montherapy as second-line treatment for locally
advanced or metastatic renal cell carcinoma. The second part is a Fruquintinib montherapy
factorial cohort study to evaluate the efficacy and safety of Fruquintinib monotherapy as for
second-line treatment of locally advanced or metastatic renal cell carcinoma.